Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
Descriptor ID |
D014409
|
MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D23.529.374.500.800 D23.529.374.750.626
|
Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Tumor Necrosis Factor
- TNF Superfamily, Member 2
- TNFalpha
- TNF-alpha
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 4 | 5 |
1995 | 1 | 0 | 1 |
1996 | 3 | 0 | 3 |
1997 | 2 | 1 | 3 |
1998 | 2 | 3 | 5 |
1999 | 2 | 4 | 6 |
2000 | 4 | 2 | 6 |
2001 | 2 | 3 | 5 |
2002 | 2 | 4 | 6 |
2003 | 3 | 1 | 4 |
2004 | 1 | 3 | 4 |
2005 | 3 | 2 | 5 |
2006 | 3 | 8 | 11 |
2007 | 4 | 6 | 10 |
2008 | 4 | 8 | 12 |
2009 | 3 | 4 | 7 |
2010 | 3 | 8 | 11 |
2011 | 3 | 4 | 7 |
2012 | 3 | 5 | 8 |
2013 | 3 | 5 | 8 |
2014 | 1 | 5 | 6 |
2015 | 2 | 4 | 6 |
2016 | 2 | 3 | 5 |
2017 | 4 | 7 | 11 |
2018 | 0 | 2 | 2 |
2019 | 3 | 4 | 7 |
2020 | 1 | 1 | 2 |
2021 | 0 | 1 | 1 |
2022 | 0 | 6 | 6 |
2023 | 0 | 2 | 2 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Diabetic retinopathy is a ceramidopathy reversible by anti-ceramide immunotherapy. Cell Metab. 2024 Jul 02; 36(7):1521-1533.e5.
-
Effect of epithelial-specific MyD88 signaling pathway on airway inflammatory response to organic dust exposure. J Immunotoxicol. 2023 12; 20(1):2148782.
-
Cytokine-Mediated Degradation of the Transcription Factor ERG Impacts the Pulmonary Vascular Response to Systemic Inflammatory Challenge. Arterioscler Thromb Vasc Biol. 2023 08; 43(8):1412-1428.
-
Protective interaction of human phagocytic APC subsets with Cryptococcus neoformans induces genes associated with metabolism and antigen presentation. Front Immunol. 2022; 13:1054477.
-
A Comparison of the Characteristics of Cytokine Storm between Lichen Planus and Oral Squamous Cell Carcinoma. Asian Pac J Cancer Prev. 2022 Nov 01; 23(11):3843-3849.
-
Effects of omega-3 supplementation on quality of life, nutritional status, inflammatory parameters, lipid profile, exercise tolerance and inhaled medications in chronic obstructive pulmonary disease. Ann Palliat Med. 2022 Sep; 11(9):2819-2829.
-
In Vitro Apical-Out Enteroid Model of Necrotizing Enterocolitis. J Vis Exp. 2022 06 08; (184).
-
Evaluation of anti-inflammatory diphenyldihaloketone EF24 in transient ischemic stroke model. Brain Inj. 2022 01 28; 36(2):279-286.
-
Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Clinical Trial. J Am Heart Assoc. 2022 02; 11(3):e023582.
-
Xylopic Acid Suppresses Adjuvant-induced Arthritis in Sprague Dawley Rats via Reduction in Serum Levels of IL-6 and TNF-alpha. Antiinflamm Antiallergy Agents Med Chem. 2022; 21(1):46-61.